XML 109 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements and Licensing Agreements, Achaogen, Inc. (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2017
USD ($)
Drug
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2006
USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Revenue earned $ 172,299 $ 120,911 $ 104,152 $ 110,304 $ 160,349 $ 110,927 $ 38,470 $ 36,874 $ 507,666 $ 346,620 $ 283,703  
Achaogen, Inc. [Member]                        
Collaborative Arrangement and Licensing Agreement [Abstract]                        
Upfront fee in the form of equity securities                       $ 1,500
Number of drugs to be developed and commercialized | Drug                 2      
Maximum amount of payments receivable for development, regulatory and commercialization milestones 49,300               $ 49,300      
Cumulative payments received 7,000               7,000      
Next prospective milestone $ 7,500               7,500      
Revenue earned                 $ 0 $ 0 $ 0